How IL-17 affects immune cells in colorectal cancer
Control of regulatory T cells by IL-17 in colorectal cancer
['FUNDING_R01'] · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · NIH-11085262
This study is looking at how a protein called IL-17 affects certain immune cells that help control inflammation in people with colorectal cancer, to see if understanding this relationship can help improve treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT (nih funded) |
| Locations | 1 site (FARMINGTON, UNITED STATES) |
| Trial ID | NIH-11085262 on ClinicalTrials.gov |
What this research studies
This research investigates the role of IL-17, a cytokine involved in inflammation, in regulating immune cells known as regulatory T cells (Tregs) in the context of colorectal cancer. The study aims to understand how IL-17 signaling influences Treg behavior and its implications for tumor development. By examining the interactions between IL-17 and Tregs, the research seeks to uncover mechanisms that could potentially alter the progression of colorectal cancer. The approach includes both laboratory experiments and analysis of immune responses in tumor environments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with colorectal cancer who may benefit from improved immunotherapy approaches.
Not a fit: Patients with non-colorectal cancers or those without active cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance anti-tumor immunity in colorectal cancer patients.
How similar studies have performed: Other research has shown promising results in targeting immune cell interactions in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
FARMINGTON, UNITED STATES
- UNIVERSITY OF CONNECTICUT SCH OF MED/DNT — FARMINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, KEPENG — UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
- Study coordinator: WANG, KEPENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer activity, anticancer immunotherapy